DGAP-News

Glycotope GmbH and Octapharma AG: Glycotope and Octapharma enter exclusive worldwide license agreement on human blood coagulation factors

DGAP-News: Glycotope GmbH / Key word(s): Agreement/Alliance
Glycotope GmbH and Octapharma AG: Glycotope and Octapharma enter
exclusive worldwide license agreement on human blood coagulation
factors

08.10.2015 / 08:30

---------------------------------------------------------------------

Glycotope and Octapharma enter exclusive worldwide license agreement on
human blood coagulation factors

- Octapharma will gain exclusive access to Glycotope's proprietary
preclinical blood coagulation factor portfolio based on the Company's
GlycoExpress(TM) platform to further expand its blood coagulation
factor and protein business

- Glycotope will receive upfront and milestone payments as well as
royalties on future product sales

- Octapharma will buy a stake in Glycotope, purchasing new shares
generated through a capital increase

- Glycotope to receive an initial payment of EUR 80 million

- Glycotope to set strategic focus on core immuno-oncology business,
including the development of these drug candidates through clinical
trials and formation of co-development partnerships

Berlin, Germany and Lachen, Switzerland, October 8th, 2015 - Glycotope
GmbH, a global leader in glyco-optimization of biopharmaceuticals, and
Octapharma AG, one of the worldwide largest human protein product
manufacturers, announced today that they have entered into an exclusive
worldwide licensing agreement for Glycotope's portfolio of preclinical
human blood coagulation factors based on its unique and proprietary
GlycoExpressTM (GEXTM) technology platform. In addition, Octapharma will
take a stake in the Company by purchasing new Glycotope shares generated
through a capital increase at a premium price. Under this agreement,
Glycotope receives an initial payment of EUR 80 million from Octapharma.

"There are significant advantages of improved recombinant blood coagulation
factors of human cell origin for the treatment of a variety of hemophilic
conditions considering immunogenic aspects and limiting pharmacokinetic
profiles of broadly used and established treatment options with currently
available recombinant blood coagulation factors", said Olaf Walter, Board
Member and Head of Octapharma's International Business Units. "Glycotope
has built a leading platform of "sugar" engineering tools that are designed
to generate novel proteins with improved glycosylation patterns and thus
offer the potential for a variety of novel treatment options such as
long-lasting treatment approaches in hemophilia. Glycotope's assets covered